IL206888A0 - Compound capable of binding s1p receptor and pharmaceutical use thereof - Google Patents
Compound capable of binding s1p receptor and pharmaceutical use thereofInfo
- Publication number
- IL206888A0 IL206888A0 IL206888A IL20688810A IL206888A0 IL 206888 A0 IL206888 A0 IL 206888A0 IL 206888 A IL206888 A IL 206888A IL 20688810 A IL20688810 A IL 20688810A IL 206888 A0 IL206888 A0 IL 206888A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor
- binding
- compound capable
- pharmaceutical use
- pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/16—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same carbon atom of an acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003306088 | 2003-08-29 | ||
JP2004110573 | 2004-04-02 | ||
JP2004169958 | 2004-06-08 | ||
JP2004198523 | 2004-07-05 | ||
PCT/JP2004/012768 WO2005020882A2 (en) | 2003-08-29 | 2004-08-27 | Compound capable of binding s1p receptor and pharmaceutical use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL206888A0 true IL206888A0 (en) | 2011-08-01 |
Family
ID=34279965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL173973A IL173973A (en) | 2003-08-29 | 2006-02-27 | (naphthalenyl-methyl)-azetidinecarboxylic acid, derivatives thereof and pharmaceutical compositions containing it |
IL206888A IL206888A0 (en) | 2003-08-29 | 2010-07-08 | Compound capable of binding s1p receptor and pharmaceutical use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL173973A IL173973A (en) | 2003-08-29 | 2006-02-27 | (naphthalenyl-methyl)-azetidinecarboxylic acid, derivatives thereof and pharmaceutical compositions containing it |
Country Status (14)
Country | Link |
---|---|
US (2) | US8791159B2 (en) |
EP (2) | EP2883865B1 (en) |
JP (4) | JP4947406B2 (en) |
KR (2) | KR101186386B1 (en) |
AU (1) | AU2004268455B2 (en) |
BR (1) | BRPI0413923A (en) |
CA (2) | CA2824106A1 (en) |
ES (2) | ES2754221T3 (en) |
IL (2) | IL173973A (en) |
MX (1) | MXPA06002310A (en) |
NO (1) | NO20061372L (en) |
NZ (1) | NZ545805A (en) |
WO (1) | WO2005020882A2 (en) |
ZA (1) | ZA200602558B (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
JP4728962B2 (en) * | 2003-05-19 | 2011-07-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Immunosuppressive compounds and compositions |
JP4947406B2 (en) * | 2003-08-29 | 2012-06-06 | 小野薬品工業株式会社 | Compound having S1P receptor binding ability and pharmaceutical use thereof |
TW200538433A (en) * | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
PL1826197T3 (en) * | 2004-12-13 | 2012-06-29 | Ono Pharmaceutical Co | Aminocarboxylic acid derivative and medicinal use thereof |
PT1863787E (en) * | 2005-03-23 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Hydogrenated benzo[c]thiophene derivatives as immunomodulators |
EP1868605A2 (en) * | 2005-03-31 | 2007-12-26 | Janssen Pharmaceutica, N.V. | Phenyl and pyridyl lta4h modulators |
CA2612661A1 (en) * | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
AR057894A1 (en) * | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | THIOPHEN DERIVATIVES |
US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
WO2007061458A2 (en) * | 2005-11-23 | 2007-05-31 | Epix Delaware, Inc. | S1p receptor modulating compounds and use thereof |
CA2646469A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1p receptor modulating compounds |
US20090324581A1 (en) | 2006-05-09 | 2009-12-31 | Daiichi Sankyo Company Limited | Heteroarylamide lower carboxylic acid derivative |
WO2007129473A1 (en) * | 2006-05-09 | 2007-11-15 | Daiichi Sankyo Company, Limited | Bicyclic aryl derivative |
RS53080B (en) | 2006-08-08 | 2014-06-30 | Kyorin Pharmaceutical Co. Ltd. | Aminophosporic acid ester derivative and s1p receptor modulator containing the same as active ingredient |
MY146775A (en) | 2006-08-08 | 2012-09-28 | Kyorin Seiyaku Kk | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
AU2011235934A1 (en) * | 2006-09-26 | 2011-11-03 | Novartis Ag | Pharmaceutical compositions comprising an S1P modulator |
EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
EP1923054A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator |
CN102579387A (en) * | 2006-09-26 | 2012-07-18 | 诺瓦提斯公司 | Pharmaceutical compositions comprising an S1P modulator |
EP2121648A2 (en) * | 2007-03-21 | 2009-11-25 | EPIX Pharmaceuticals, Inc. | S1p receptor modulating compounds and use thereof |
JP2010525016A (en) * | 2007-04-23 | 2010-07-22 | ノバルティス アーゲー | Phthalazine and isoquinoline derivatives having SLP receptor modulating activity |
ATE505454T1 (en) * | 2007-09-20 | 2011-04-15 | Amgen Inc | 1-(4-(4-BENZYLBENZAMIDE)-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND CORRESPONDING COMPOUNDS AS S1P RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISEASES |
RU2014151622A (en) | 2007-10-05 | 2015-08-20 | Акусела Инк. | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES |
WO2009099174A1 (en) | 2008-02-07 | 2009-08-13 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
HUE030424T2 (en) | 2008-07-23 | 2017-05-29 | Arena Pharm Inc | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
ES2583630T3 (en) | 2008-08-27 | 2016-09-21 | Arena Pharmaceuticals, Inc. | Derivatives of substituted tricyclic acid as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
WO2010042998A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
CA2740484C (en) * | 2008-10-17 | 2021-09-21 | Akaal Pharma Pty Ltd | S1p receptors modulators and their use thereof |
BRPI0922135B1 (en) | 2008-12-05 | 2021-07-13 | Astellas Pharma Inc | 2H-CROMENE COMPOUND OR A SALT THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUND AND USE OF THE SAME TO PREVENT OR TREAT A DISEASE INDUCED BY UNDESIRABLE LYMPHOCYTE INFILTRATION ASSOCIATED WITH S1P1 |
ES2897527T3 (en) | 2009-07-02 | 2022-03-01 | Acucela Inc | Pharmacology of visual cycle modulators |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
AR077969A1 (en) * | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | DERIVATIVES OF (TIO) MORFOLINA COMOMODULADORES DE S1P |
NZ599966A (en) * | 2009-11-24 | 2014-09-26 | Allergan Inc | Novel compounds as receptor modulators with therapeutic utility |
CN103221391B (en) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R) preparation method of -2- (7- (4- cyclopenta -3- (trifluoromethyl) benzyls oxygroup) -1,2,3,4- tetrahydro cyclopentyl diene simultaneouslies [b] indol-3-yl) acetic acid and its salt |
US8791100B2 (en) * | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
JP2013521301A (en) | 2010-03-03 | 2013-06-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Process for the preparation of S1P1 receptor modulators and their crystalline forms |
CN109745313A (en) | 2010-08-11 | 2019-05-14 | 德雷克塞尔大学 | The D3 dopamine-receptor stimulant for treating dyskinesia in Parkinson's disease |
PT2672823T (en) | 2011-02-07 | 2016-11-21 | Biogen Ma Inc | S1p modulating agents |
CA2833313A1 (en) * | 2011-04-14 | 2012-10-18 | Allergan, Inc. | Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
MX2013012211A (en) * | 2011-04-18 | 2013-12-09 | Allergan Inc | Substituted bicyclic methyl amine derivatives as sphingosine-1-phosphate receptors modulators. |
PT2762466T (en) | 2011-09-29 | 2017-07-31 | Ono Pharmaceutical Co | Phenyl derivative |
CN104703598A (en) | 2012-01-20 | 2015-06-10 | 奥克塞拉有限公司 | Substituted heterocyclic compounds for disease treatment |
ES2671194T3 (en) | 2012-07-27 | 2018-06-05 | Biogen Ma Inc. | Compounds that are S1P modulating agents and / or ATX modulating agents |
US9850206B2 (en) | 2012-11-20 | 2017-12-26 | Biogen Ma Inc. | S1P and/or ATX modulating agents |
CN105026360B (en) * | 2013-01-29 | 2017-08-25 | 比奥根Ma公司 | S1P conditioning agents |
RU2639875C2 (en) | 2013-03-26 | 2017-12-25 | Оно Фармасьютикал Ко., Лтд. | Phenyl derivative |
EP2990055B1 (en) | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
US11471436B2 (en) | 2014-12-04 | 2022-10-18 | Ono Pharmaceutical Co., Ltd. | Dihydronaphthalene derivative |
CN107405332A (en) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | Treatment and S1P1The method of receptor related illness |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
CN108368107B (en) * | 2015-08-28 | 2021-11-26 | 艾伯维公司 | Fused heterocyclic compounds as S1P modulators |
PL3416962T3 (en) * | 2016-02-15 | 2021-11-22 | Sanofi | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
EP3582772A1 (en) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
MA47503A (en) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES OF THE INTESTINE WITH EXTRAINTESTINAL MANIFESTATIONS |
TWI789495B (en) | 2018-02-22 | 2023-01-11 | 日商小野藥品工業股份有限公司 | Compound having sip5 receptor agonist activity |
EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
WO2021033729A1 (en) | 2019-08-20 | 2021-02-25 | 小野薬品工業株式会社 | Salt and crystal form of compound having agonistic activity to s1p5 receptor |
WO2021157682A1 (en) | 2020-02-06 | 2021-08-12 | 田辺三菱製薬株式会社 | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome |
US20230148589A1 (en) * | 2020-03-31 | 2023-05-18 | Lg Chem, Ltd. | Composition for protecting islet transplantation |
CA3201000A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
TWI823341B (en) * | 2021-04-14 | 2023-11-21 | 南韓商Lg化學股份有限公司 | Novel method for preparing sphingosine-1-phosphate receptor agonist |
CN117242057A (en) * | 2021-04-14 | 2023-12-15 | 株式会社Lg化学 | Process for preparing intermediates useful in the synthesis of sphingosine-1-phosphate receptor agonists |
KR20220142388A (en) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | Novel method of preparing sphinosine-1-phosphate receptor agonist |
WO2024025862A1 (en) * | 2022-07-28 | 2024-02-01 | The Board Of Regents Of The University Of Oklahoma | Agonists of peroxisome proliferator-activated receptor alpha (ppara) and methods of use |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (en) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
JPS58162949A (en) * | 1982-03-20 | 1983-09-27 | Konishiroku Photo Ind Co Ltd | Color photographic sensitive silver halide material |
DE3508398A1 (en) * | 1985-03-08 | 1986-11-06 | Hoechst Ag, 6230 Frankfurt | FUNGICIDES BASED ON 3- (HETERO) -ARYLPROPYLAMINES AND NEW (HETERO) -ARYL-PROPYLAMINS AND METHOD FOR THE PRODUCTION THEREOF |
EP0411751A1 (en) * | 1989-06-06 | 1991-02-06 | Beecham Group p.l.c. | Renin inhibitory peptides |
EP0466254A1 (en) * | 1990-07-11 | 1992-01-15 | Merck & Co. Inc. | 2-naphthyl-carbapenems |
DK0627406T3 (en) | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propanediol compounds and immunosuppressants |
IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicyclic compounds and pharmaceutical compositions containing them |
US5789595A (en) * | 1994-11-01 | 1998-08-04 | Terumo Kabushiki Kaisha | Tetrahydroisoquinoline derivative and medical preparation containing the same |
DE19527568A1 (en) * | 1995-07-28 | 1997-01-30 | Merck Patent Gmbh | Endothelin receptor antagonists |
DE69839305T2 (en) | 1997-02-27 | 2009-04-09 | Takeda Pharmaceutical Co. Ltd. | AMIN DERIVATIVES, THEIR PREPARATION AND USE AS INHIBITORS OF THE PRODUCTION OF AMYLOID BETA |
JP2002518368A (en) | 1998-06-17 | 2002-06-25 | デュポン ファーマシューティカルズ カンパニー | Cyclic hydroxamic acids as metalloproteinase inhibitors |
EP1218336A2 (en) | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
US6458822B2 (en) * | 2000-03-13 | 2002-10-01 | Pfizer Inc. | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
ATE315558T1 (en) | 2000-08-29 | 2006-02-15 | Allergan Inc | COMPOUNDS WITH CYTOCHROME P450RA1 INHIBITIVE ACTIVITY |
WO2002018377A1 (en) * | 2000-08-29 | 2002-03-07 | Pharmacia Corporation | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
AU2001288819A1 (en) * | 2000-09-11 | 2002-03-26 | Genentech, Inc. | Amidine inhibitors of serine proteases |
US7115608B2 (en) * | 2000-09-19 | 2006-10-03 | Centre National De La Recherche Schentifique | Pyridinone and pyridinethione derivatives having HIV inhibiting properties |
WO2002028821A2 (en) | 2000-10-05 | 2002-04-11 | Bayer Aktiengesellschaft | Propionic acid derivatives with ppar-alpha activating properties |
WO2002092068A1 (en) * | 2001-05-10 | 2002-11-21 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
US20050143372A1 (en) * | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
DE60329073D1 (en) * | 2002-01-18 | 2009-10-15 | Merck & Co Inc | EDG RECEPTOR AGONISTS |
DE60330047D1 (en) * | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
EP1469863A2 (en) * | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
PT1501804E (en) * | 2002-04-26 | 2009-10-29 | Hoffmann La Roche | Isoquinoline derivatives mao-b inhibitors |
CA2488117A1 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
DE60321207D1 (en) * | 2002-09-19 | 2008-07-03 | Lilly Co Eli | Diaryläther als opioid-rezeptor antagonisten |
JP4594611B2 (en) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | Receptor function regulator |
DE60335827D1 (en) | 2002-12-20 | 2011-03-03 | Merck Sharp & Dohme | 1- (AMINO) INDANE AS EDG RECEPTOR AGONISTS |
US20060135403A1 (en) * | 2002-12-24 | 2006-06-22 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
US7060697B2 (en) * | 2003-05-19 | 2006-06-13 | Irm Llc | Immunosuppressant compounds and compositions |
PE20050158A1 (en) * | 2003-05-19 | 2005-05-12 | Irm Llc | IMMUNOSUPPRESSOR COMPOUNDS AND COMPOSITIONS |
JP4728962B2 (en) * | 2003-05-19 | 2011-07-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Immunosuppressive compounds and compositions |
DE10335092B3 (en) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituted benzoylureido-o-benzoylamides, process for their preparation and their use |
CN101407471A (en) * | 2003-08-29 | 2009-04-15 | 小野药品工业株式会社 | Compound capable of binding S1P receptor and pharmaceutical use thereof |
JP4947406B2 (en) * | 2003-08-29 | 2012-06-06 | 小野薬品工業株式会社 | Compound having S1P receptor binding ability and pharmaceutical use thereof |
-
2004
- 2004-08-27 JP JP2005513544A patent/JP4947406B2/en not_active Expired - Fee Related
- 2004-08-27 ES ES14190717T patent/ES2754221T3/en active Active
- 2004-08-27 NZ NZ545805A patent/NZ545805A/en not_active IP Right Cessation
- 2004-08-27 KR KR1020067004275A patent/KR101186386B1/en not_active IP Right Cessation
- 2004-08-27 EP EP14190717.0A patent/EP2883865B1/en active Active
- 2004-08-27 MX MXPA06002310A patent/MXPA06002310A/en active IP Right Grant
- 2004-08-27 EP EP04772717.7A patent/EP1661881B1/en not_active Not-in-force
- 2004-08-27 CA CA2824106A patent/CA2824106A1/en not_active Abandoned
- 2004-08-27 KR KR1020117028378A patent/KR20110140139A/en not_active Application Discontinuation
- 2004-08-27 WO PCT/JP2004/012768 patent/WO2005020882A2/en active Application Filing
- 2004-08-27 CA CA2537093A patent/CA2537093C/en not_active Expired - Fee Related
- 2004-08-27 AU AU2004268455A patent/AU2004268455B2/en not_active Ceased
- 2004-08-27 BR BRPI0413923-2A patent/BRPI0413923A/en not_active IP Right Cessation
- 2004-08-27 ES ES04772717.7T patent/ES2527117T3/en active Active
-
2006
- 2006-02-27 IL IL173973A patent/IL173973A/en active IP Right Grant
- 2006-03-27 NO NO20061372A patent/NO20061372L/en not_active Application Discontinuation
- 2006-03-28 ZA ZA2006/02558A patent/ZA200602558B/en unknown
-
2010
- 2010-07-08 IL IL206888A patent/IL206888A0/en unknown
- 2010-09-10 US US12/879,158 patent/US8791159B2/en not_active Expired - Fee Related
- 2010-10-28 JP JP2010242153A patent/JP5381959B2/en not_active Expired - Fee Related
-
2013
- 2013-03-12 JP JP2013048980A patent/JP5817763B2/en not_active Expired - Fee Related
-
2014
- 2014-06-04 US US14/295,799 patent/US20140288034A1/en not_active Abandoned
- 2014-09-18 JP JP2014190026A patent/JP5928915B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL206888A0 (en) | Compound capable of binding s1p receptor and pharmaceutical use thereof | |
EP1760071A4 (en) | Compound having s1p receptor binding potency and use thereof | |
IL176248A0 (en) | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | |
IL170758A0 (en) | 7-amino-isoindolyl compounds and their pharmaceutical uses | |
HK1085643A1 (en) | Uses and compositions for administration of capsaicin | |
IL183308A (en) | Cyclopropyl leucinamide compounds and use thereof for preparation of medicaments | |
IL173639A0 (en) | Ppar-activating compound and pharmaceutical composition containing same | |
HK1130254A1 (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | |
EP1682136A4 (en) | Therapeutic compounds and uses thereof | |
IL183986A0 (en) | Pharmaceutical compounds and compositions | |
IL174144A0 (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
GB0416728D0 (en) | Medicinal use of receptor ligands | |
GB0305150D0 (en) | Use of therapeutic compounds | |
GB0410470D0 (en) | Pharmaceutical compound and polymorphs thereof | |
EP1633749A4 (en) | Deazaflavin compounds and methods of use thereof | |
EP1663201A4 (en) | A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | |
HK1094153A1 (en) | Nasal pharmaceutical composition of piribedil | |
ZA200603126B (en) | Pharmaceutical compositions for therapeutic use | |
IL177751A0 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use | |
HK1087623A1 (en) | Combination of antidiabetic drugs | |
GB0312844D0 (en) | Use of compounds in medicine | |
GB0425532D0 (en) | Therapeutic compounds and methods for their preparation and use | |
SI1661890T1 (en) | Ppar-activating compound and pharmaceutical composition containing same | |
GB0414194D0 (en) | Medicinal use of receptor ligands | |
GB0414196D0 (en) | Medicinal use of receptor ligands |